| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.05 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.07 | 0.05 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.067 | 0.05 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.05 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.068 | 0.05 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.05 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.068 | 0.05 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | 0.063 | 0.05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.11 | 0.06 |